Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

Möricke, Anja; Zimmermann, Martin; Reiter, Alfred; Henze, Günter; Schrauder, André; Gadner, Helmut; Ludwig, Wolf Dieter; Ritter, J.; Harbott, Jochen; Mann, Georg; Klingebiel, Thomas; Zintl, F; Niemeyer, Charlotte M.; Kremens, Bernhard; Niggli, Felix; Niethammer, D; Welte, Karl; Stanulla, Martin; Odenwald, E.; Riehm, H.; Schrappe, Martin

doi:10.1038/leu.2009.257

Cited by 461 publications

(345 citation statements)

References 74 publications

Supporting

Mentioning

304

Contrasting

Unclassified

Order By: Relevance

“…This result is similar to our previous study [24]. Compared to studies in high income and low-income countries our finding is relatively high for T-lineage ALL [25][26][27][28][29][30][31][32][33][34][35]. Expression of CD10 and CD34 also varies in different studies ( Table 1).…”

Section: Discussionsupporting

confidence: 76%

Detection of CD10, CD34 and their combined expression on Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia

Hirshoren¹,

Veerman²,

Sutaryo³

et al. 2012

J Cancer Ther Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 76%

Detection of CD10, CD34 and their combined expression on Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia

Hirshoren¹,

Veerman²,

Sutaryo³

et al. 2012

J Cancer Ther Res

View full text Add to dashboard Cite

show abstract

“…Compared with precursor B-cell ALL, the prognostic markers for T-cell ALL are relatively inadequate for treatment planning. In various Berlin-Frankfurt-Mu "nster (BFM)-like treatment protocols, patient stratification is based primarily on patient response to glucocorticoid-based prophase therapy and minimal residual disease analysis [9,39]. Two reports that identified high-risk T-cell ALL with primary failure may provide an avenue for molecular risk-directed therapy for T-cell ALL [35,36].…”

Section: Discussionmentioning

confidence: 99%

“…Although the use of intensive chemotherapy has enabled patients with T-cell ALL to fare as well as patients with B-cell precursor ALL in some studies, the outcomes are significantly worse for the patients with T-cell ALL in most treatment protocols [3][4][5][6][7][8][9][10][11][12][13][14][15]. Chromosomal alterations, including numbers and translocations, have helped to classify pediatric patients with B-cell precursor ALL and improve treatment outcomes in the past three decades [16].…”

Section: Introductionmentioning

confidence: 99%

Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T‐cell acute lymphoblastic leukemia

Yang

Hsiao

Chen

et al. 2011

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundThe absence of biallelic TCRγ deletion (ABD) is a characteristic of early thymocyte precursors before V(D)J recombination. The ABD was reported to predict early treatment failure in T‐cell acute lymphoblastic leukemia (ALL). This study aimed to investigate its prognostic value in Taiwanese patients with T‐cell ALL.ProcedureForty‐five children with T‐cell ALL were enrolled from six medical centers in Taiwan. Quantitative DNA polymerase chain reaction (Q‐PCR) was performed to check the status of TCRγ deletion. The threshold for homozygous deletions by Q‐PCR was defined as a fold‐change <0.35.ResultsABD was found in 20 patients [20:45] who had higher incidences of induction failure than those without ABD (P = 0.03; hazard ratio [HR] = 8.13; 95% confidence interval [95% CI] = 1.23–53.77) after multivariate regression analysis. Patents with ABD also had inferior EFS and OS (P = 0.071 and 0.0196, respectively). Multivariate Cox analysis indicated that the association between ABD and overall survival was independent of age and leukocyte count on presentation (P = 0.036; HR = 4.25; 95% CI = 1.10–16.42).ConclusionsThe absence of TCRγ deletion is a predictor of a poor response to induction chemotherapy for pediatric patients with T‐cell ALL in Taiwan. Providing patients with T‐cell ALL and ABD with alternative regimens may be worthwhile to test in future clinical trials. Pediatr Blood Cancer 2012; 58: 846–851. © 2011 Wiley Periodicals, Inc.

show abstract

“…3 The addition of an anthracycline as a fourth drug is variable. In some protocols all patients receive an anthracycline; 4 in other protocols it is reserved for high-risk cases. 5 The majority of clinical trials in the 1980s and 1990s had used prednisone or prednisolone (PRED) for remission induction therapy in childhood ALL.…”

Section: Introductionmentioning

confidence: 99%

Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis

et al. 2011

View full text Add to dashboard Cite

This systematic review and meta-analysis compared the efficacy and toxicity of dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute lymphoblastic leukemia (ALL). We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and PRED during induction therapy for childhood ALL. A total of eight studies were eligible for inclusion in this meta-analysis. DEX, in comparison with PRED, reduced events (that is, death from any cause, refractory or relapsed leukemia, or second malignancy; risk ratio (RR) 0.80; 95% confidence interval (CI), 0.68-0.94) and central nervous system relapse (RR 0.53; 95% CI, 0.44-0.65), but did not alter bone marrow relapse (RR 0.90; 95% CI, 0.69-1.18) or overall mortality (RR 0.91; 95% CI, 0.76-1.09). Patients receiving DEX had a higher risk of mortality during induction (RR 2.31; 95% CI, 1.46-3.66), neuro-psychiatric adverse events (RR 4.55; 95% CI, 2.45-8.46) and myopathy (RR 7.05; 95% CI, 3.00-16.58). There was no statistically significant difference in the risk of osteonecrosis, sepsis, fungal infection, diabetes or pancreatitis. DEX in induction therapy for children with ALL is more efficacious than PRED. However, DEX is also associated with more toxicity, and currently it remains unclear whether shortterm superiority of DEX will also result in better overall survival.

show abstract

Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

Cited by 461 publications

References 74 publications

Detection of CD10, CD34 and their combined expression on Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia

Detection of CD10, CD34 and their combined expression on Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia

Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T‐cell acute lymphoblastic leukemia

Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis

Contact Info

Product

Resources

About